| Dr Roberto Carlos Iglesias, MD | |
|
520 Mary St Ste 520, Evansville, IN 47710-1682 | |
| (812) 424-8231 | |
| (812) 435-8794 |
| Full Name | Dr Roberto Carlos Iglesias |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 21 Years |
| Location | 520 Mary St Ste 520, Evansville, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336166297 | NPI | - | NPPES |
| 201221530 | Medicaid | IN | |
| 000000863595 | Other | IN | ANTHEM BLUE CROSS BLUE SHIELD |
| 7100298220 | Medicaid | KY | |
| 01073663 | Other | IN | INDIANA STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 01073663A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| Ascension St Vincent Evansville | Evansville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Evansville Surgical Associates Inc | 1557346723 | 39 |
News Archive
Writing in the Global Health Technologies Coalition's (GHTC) "Breakthroughs" blog, GHTC Communications Officer Kim Lufkin summarizes the group's annual congressional briefing, "which focused on how U.S. policymakers can protect the nation's investments in global health research in upcoming budget discussions."
A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. This finding may save patients from undergoing unnecessary workup and treatment according to a study published in the August 2009 issue of Mayo Clinic Proceedings.
Fresenius Kabi Pharmaceuticals Holding, Inc.,, the parent company of APP Pharmaceuticals, Inc., announced today that APP and other Fresenius Kabi companies have entered into license and settlement agreements with sanofi-aventis covering patents that apply to Eloxatin® (oxaliplatin injection and oxaliplatin for injection).
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
› Verified 3 days ago
| Entity Name | Evansville Surgical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497707517 PECOS PAC ID: 1557346723 Enrollment ID: O20040622000449 |
News Archive
Writing in the Global Health Technologies Coalition's (GHTC) "Breakthroughs" blog, GHTC Communications Officer Kim Lufkin summarizes the group's annual congressional briefing, "which focused on how U.S. policymakers can protect the nation's investments in global health research in upcoming budget discussions."
A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. This finding may save patients from undergoing unnecessary workup and treatment according to a study published in the August 2009 issue of Mayo Clinic Proceedings.
Fresenius Kabi Pharmaceuticals Holding, Inc.,, the parent company of APP Pharmaceuticals, Inc., announced today that APP and other Fresenius Kabi companies have entered into license and settlement agreements with sanofi-aventis covering patents that apply to Eloxatin® (oxaliplatin injection and oxaliplatin for injection).
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roberto Carlos Iglesias, MD 520 Mary St Ste 520, Evansville, IN 47710-1682 Ph: (812) 424-8231 | Dr Roberto Carlos Iglesias, MD 520 Mary St Ste 520, Evansville, IN 47710-1682 Ph: (812) 424-8231 |
News Archive
Writing in the Global Health Technologies Coalition's (GHTC) "Breakthroughs" blog, GHTC Communications Officer Kim Lufkin summarizes the group's annual congressional briefing, "which focused on how U.S. policymakers can protect the nation's investments in global health research in upcoming budget discussions."
A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. This finding may save patients from undergoing unnecessary workup and treatment according to a study published in the August 2009 issue of Mayo Clinic Proceedings.
Fresenius Kabi Pharmaceuticals Holding, Inc.,, the parent company of APP Pharmaceuticals, Inc., announced today that APP and other Fresenius Kabi companies have entered into license and settlement agreements with sanofi-aventis covering patents that apply to Eloxatin® (oxaliplatin injection and oxaliplatin for injection).
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
› Verified 3 days ago
Dawn M Burgess, RNFA Surgery Medicare: Not Enrolled in Medicare Practice Location: 2701 Lincoln Ave, Evansville, IN 47714 Phone: 812-476-4400 Fax: 812-476-0300 | |
Dr. Santi Vibul, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 520 Mary St, Suite 520, Evansville, IN 47710 Phone: 812-424-8231 Fax: 812-435-8782 | |
Dr. Samir K. Gupta, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 520 Mary St Ste 520, Evansville, IN 47710 Phone: 812-424-8231 Fax: 812-435-8794 | |
Dr. Anthony David Kaiser, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 520 Mary St Ste 520, Evansville, IN 47710 Phone: 812-424-8231 Fax: 812-435-8794 | |
Dr. Brian W Schymik, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 520 Mary St Ste 520, Evansville, IN 47710 Phone: 812-424-8231 Fax: 812-435-8794 | |
Dr. Prasad V Gade, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 520 Mary St Ste 520, Evansville, IN 47710 Phone: 812-424-8231 Fax: 812-435-8794 | |
Dr. Katherine Mckenna Kottwitz, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 111 S Green River Rd Ste F, Evansville, IN 47715 Phone: 812-436-1203 |